Abstract
Introduction:
Porcine circovirus 2 (PCV2) emerged more than three decades ago as one of the most impactful pathogens in the swine industry. Despite being a DNA virus, one of the hallmarks of PCV2 is its high evolutionary rate, which has led to the emergence of different genotypes, each exhibiting varying degrees of evolutionary success. Current knowledge suggests the occurrence of three main waves of genotype dominance, alternating over time (i.e., PCV2a, PCV2b, and PCV2d), alongside less prevalent genotypes. However, although PCV2d is currently the most common genotype nowadays, the others continue being circulating in the pig population.
Methods:
The present study reconsidered the epidemiological and evolutionary patterns of PCV2 genotypes using phylodynamic analyses, benefiting from an almost 10-fold increase in ORF2 sequence availability compared to previous studies. Additionally, a phylogeographic analysis was performed to investigate viral dispersal patterns and frequency, and the selective pressures acting on the capsid protein were estimated and compared among genotypes.
Results:
While successive emergence of major genotypes was confirmed, this study extends previous findings by revealing subsequent prevalence fluctuations of PCV2a and PCV2b after their initial decline. This evolutionary process may represent an example of balancing selection, specifically negative frequency-dependent selection, where a genotype fitness diminishes as it becomes more common, and vice versa. Variations in genotype- or clade-specific immunity—affected by the local prevalence of viral groups—combined with the periodic introduction of strains that have independently evolved in different regions, may have led to fluctuations in the population dynamics of major genotypes over time. These fluctuations were associated with ongoing evolution and variations in the capsid amino acid profile.
Discussion:
These findings have profound implications for future control strategies. Although PCV2d remains the most prevalent and widespread genotype, other genotypes should not be neglected. Control strategies should thus target the entire PCV2 population, with a focus on fostering broader and more cross-protective immunity.
1 Introduction
Porcine circovirus 2 (PCV2) is a small, non-enveloped virus belonging to the Circoviridae family, within the genus Circovirus (). It is one of the smallest known viruses, characterized by a circular single-stranded DNA (ssDNA) genome that contains a limited number of open reading frames (ORFs). Among these, ORF1 is particularly important, as it codes—through alternative splicing—for Rep and Rep’ proteins, which are involved in viral genome replication. ORF2 encodes the Cap protein, the only constituent of the viral capsid, which mediates viral attachment to host cells and contains the main targets of the host immune response, including neutralizing antibodies and cell-mediated immunity epitopes. Due to its biological relevance and high genetic variability, ORF2 is the most sequenced and investigated PCV2 gene. It is commonly used for molecular epidemiology studies and for PCV2 genotyping (). Other ORFs (ORF3-6) have been shown to be transcribed and translated, playing essential roles in apoptosis regulation and interfering with host signaling pathways at different levels (; ; ; ; ). Initially associated with postweaning multisystemic wasting syndrome (PMWS, currently known as PCV2 systemic disease, PCV2-SD) in the early 90s, PCV2 was thereafter involved in the pathogenesis of other clinical conditions such as PCV2 reproductive disease (PCV2-RD) and porcine dermatitis and nephropathy syndrome (PDNS). These three clinical entities (PCV2-SD, PCV2-RD, and PDNS) are collectively named porcine circovirus diseases (PCVDs) (). These PCVDs are multifactorial, but most PCV2 infections are subclinical (PCV2 subclinical infection, PCV2-SI). Paradoxically, PCV2-SI has an economic impact that is even higher than clinical infections on farm profitability, due to decreased average daily weight gain and increased susceptibility to co-infections (). The introduction of mass PCV2 vaccination in the first decade of the 2000s proved extremely effective, not only in preventing overt clinical signs but also in limiting losses in subclinically infected animals. Since then, vaccination has been intensively and routinely applied to the point of becoming a standard part of management on almost all intensive pig farms worldwide ().
Despite the widespread benefits of vaccination, PCV2 has continued circulating, spreading, and evolving globally. Episodes of vaccine or vaccination apparent failure have been periodically reported, occasionally attributed to the lack of cross-protection provided by commercial vaccines based on the capsid protein of PCV2a genotype against other genotypes (; ). Nowadays there is a broad consensus in the literature regarding the efficacy of current vaccines; the so-called vaccination failures are most likely due to improper vaccination management since evidence suggests that variable but significant cross-protection among strains and genotypes does exist (, ,; ). This variability could nevertheless have played a role in shaping the epidemiology of PCV2, influencing the virus ongoing evolution and persistence across different regions (; ). Like other ssDNA viruses, PCV2 exhibits a high evolutionary potential due to both high mutation and recombination rates, leading to the emergence of several genetic variants. These variants are classified into genotypes based on a combination of genetic distance, phylogenetic analysis, and comparison with reference strains (). Currently, nine genotypes have been proposed, varying in frequency, geographical distribution, and potentially biological characteristics (; ). However, differences in virulence and immunogenicity among these genotypes are still debated, and within-genotype heterogeneity also occurs.
Among PCV2 genotypes, only three (PCV2a, PCV2b, and PCV2d) are considered major genotypes due to their high prevalence, worldwide distribution, and persistent circulation over the years (; ). The first genotype to be identified was PCV2a, which was displaced as the dominant one by PCV2b around 2000–2003 (first genotype shift) and finally by PCV2d after 2010–2014 (second genotype shift). The rise of PCV2d, which appears to be progressively replacing other genotypes, has been linked, at least to some extent, to the widespread application of PCV2a-based vaccines (,). These vaccines may confer differential immunity against various genotypes, which, although effective from a clinical perspective, might provide an evolutionary advantage to certain strains. This hypothesis is supported by changes in relative genotype prevalence following the introduction of vaccination, the presence of differential selective pressures, and within-genotype clade selection (; ; ; ). Moreover, experimental studies have provided evidence of more effective protection against homologous strains compared to heterologous challenges, and vaccination performed combining strains belonging to different genotypes seems to confer better protection ().
However, despite the described trends, all major genotypes are still consistently reported, albeit with varying frequencies, across the globe. As a result of the extensive short- and long-distance dispersal of PCV2 strains, the co-circulation and competition of different strains and genotypes—each potentially exhibiting different biological and immunological features—have likely contributed to shaping the current epidemiological landscape in a less predictable manner than what might be expected in the presence of vaccine-derived immunity alone. Nonetheless, existing studies reconstructing the dynamics of PCV2 genotypes over time on a worldwide scale are almost 10 years old.
Therefore, the purpose of the present study was to investigate the population dynamics and evolution of PCV2 by taking advantage of the ever-increasing availability of sequences collected from a broader range of countries across different continents. This approach aimed to provide an updated view of the current PCV2 phylodynamic scenario.
2 Materials and methods
2.1 Datasets preparation
All complete or nearly complete PCV2 ORF2 sequences for which collection date and country of origin were available were downloaded from GenBank. Sequences containing premature stop codons and frameshift mutations, identified using dedicated Python scripts, were removed from the dataset. A preliminary alignment was performed at the amino acid level using the MAFFT method () implemented in TranslatorX (), then sequences were back-translated to DNA. Sequences with regions of poor-quality alignment were also removed from the database through visual inspection. The selected sequences were then aligned with a set of reference sequences suggested by using the same program. A maximum likelihood (ML) phylogenetic tree was reconstructed with IQ-Tree (), selecting the substitution model with the lowest Akaike information criterion (AIC) calculated by the software. The robustness of the inferred clades was assessed by performing 10,000 ultrafast bootstrap replicates. Sequences were classified into genotypes based on clustering with reference sequences, and independent datasets were generated accordingly. The absence of a significant within-dataset recombination signal was assessed using GARD ().
Since the main aim of the study was to focus on the current dynamics of the most epidemiologically relevant clades rather than to reconstruct the ancient history and origin of genotypes, only strains strongly clustering within recognized genotypes were considered. Strains that were part of minor clades, located on intermediate branches among genotypes, or with limited bootstrap support were not included. Although seemly arbitrary, these inclusion criteria were applied with the understanding that emphasizing groups of strains with limited or negligible epidemiological relevance—potential epidemiological dead ends—could come at the risk of genotypes misclassification or inclusion of potential recombinant strains, whose identification is often challenging and could negatively impact the accuracy of parameter estimates.
For this reason, PCV2c and the so-called PCV2d-1 clade were not considered - although of historical importance - due to the limited sequence availability and current limited relevance. PCV2i was also not explicitly considered since it closely clustered with PCV2a and some PCV2i strains were initially classified within PCV2a. However, to avoid classification assumptions affecting results reliability, analyses were repeated considering PVC2i as an independent genotype.
Sampling and sequencing bias due to different resource availability or attitudes to perform molecular epidemiology investigations is known to occur (; ). To obtain more balanced datasets and reduce the computational burden, each genotype-specific dataset was down-sampled by randomly selecting up to four sequences for each country-year pair (Country-year dataset). Additionally, another random dataset of 500 sequences was generated (Balanced dataset) for each genotype by randomly selecting sequences according to a probability function that accounted for the time-country composition of the original dataset. No down-sampling was performed on minor genotypes due to their limited number.
2.2 Phylodynamic and phylogeographic analysis
The selected datasets were analyzed to estimate several population parameters, including the time to the most recent common ancestor (tMRCA), evolutionary rate, and viral population dynamics, using the Bayesian serial coalescent approach implemented in BEAST 1.10 (). For each dataset, the nucleotide substitution model was chosen based on the Bayesian Information Criterion (BIC) score calculated using JmodelTest2 (). The lognormal relaxed molecular clock () model was preferred to the strict molecular clock by calculating the marginal likelihood estimation through path-sampling and stepping-stone methods, as recommended by . The non-parametric Bayesian Skygrid model was used to reconstruct viral population changes over time, focusing on relative genetic diversity (effective population size multiplied by generation time; Ne x τ) ().
For the genotype-specific datasets, a discrete state phylogeographic analysis was also conducted, following the method described by . This analysis implemented an asymmetric migration model with Bayesian stochastic search variable selection (BSSVS) to identify the most parsimonious representation of the viral spread and calculate a Bayesian Factor (BF) that indicates the statistical significance of inferred migration paths between geographic regions. Due to the sparse nature of sequence-country combinations and likely gaps in sampling from several countries, the datasets were also analyzed by aggregating countries into macro-geographical areas based on spatial proximity and geopolitical factors (e.g., Africa, Asia, Europe, North America, Oceania, and South America).
Two independent runs of 100 million generations were performed. The log and tree files were merged using LogCombiner after discarding 20% as burn-in. The results were analyzed using Tracer 1.7 and were considered valid only if the estimated sample size (ESS) exceeded 200 and the convergence and mixing were adequate. Parameter estimates were summarized using mean values and 95% highest posterior density (HPD) intervals. Maximum clade credibility (MCC) trees were constructed and annotated using TreeAnnotator (part of the BEAST package). SpreaD3 () was utilized to calculate the BF associated with each migration route. All non-zero transition rates between countries were deemed significant if the calculated BF exceeded 5. Additional summary statistics and graphical outputs were generated using custom R and Python scripts.
To estimate the relevance of major genotypes in different geographic areas over time, the proportion of lineages circulating in each region was reconstructed by analyzing the MCC tree annotated with ancestral state reconstruction. The number of branches assigned to a specific area, based on the highest posterior probability, was counted at different time points. Specifically, 50 equally spaced time intervals were defined from the most recently collected sample to the tMRCA. A smoothing function was applied to depict a continuous trend over time and to mitigate local, inconsistent trends that could arise due to estimation uncertainty.
2.3 Selective pressure analysis
The analysis of pervasive selective pressures on the Cap protein across major genotypes was conducted using FUBAR (), while MEME was utilized to identify sites under episodic diversifying selection (). A posterior probability (PP) > 0.9 was deemed significant for FUBAR, and a p-value <0.05 was used for MEME. To assess differences in selective pressure strength among genotypes, contrast-FEL was employed (). A false discovery rate (FDR)-corrected q-value of 0.2 was set as the threshold for detecting overall site-specific differences in selective pressure, with a p < 0.05 used for comparisons between genotype pairs. All analyses were performed using HyPhy () or the Datamonkey web server (). The identified features of interest were mapped onto the capsid quaternary structure, for which the 3R0R assembly was downloaded from PDB and visualized and edited in Chimera ().
3 Results
3.1 Sequence dataset
A total of 8,283 sequences were included in the final dataset (Supplementary Table S1). A summary of genotype-specific metadata of the included strains is provided in Table 1. After database refinement, no evidence of recombination was detected in each dataset.
Table 1
| Genotype | N | Years | Countries | tMRCA | Evolutionary rate |
|---|---|---|---|---|---|
| PCV-2a | 1,091 | 1996–2024 | Belgium(3), Brazil(4), Canada(10), CapeVerde(2), Chile(10), China(413), Colombia(2), Croatia(2), Democratic Republic of the Congo(3), Ethiopia(2), France(6), Germany(16), India(3), Italy(18), Japan(40), Malaysia(2), Mexico(4), Mongolia(1), Mozambique(1), Netherlands(3), Nigeria(8), Poland(6), Portugal(6), Romania(5), Russia(1), Senegal(2), Serbia(3), Slovakia(5), South Korea(40), Spain(3), Switzerland(1), Taiwan(14), Tanzania(2), Thailand(7), USA(433), Ukraine(7), United Kingdom(2), Vietnam(1) | 1940.381 [95HPD:1919.225–1958.202] | 9.154×10−4 [95HPD:7.955×10−4-1.046×10−3] |
| PCV-2b | 2,670 | 1999–2024 | Argentina(14), Australia(2), Belarus(1), Belgium(2), Brazil(64), Canada(9), Chile(7), China(1184), Croatia(12), Cuba(1), Denmark(9), Ethiopia(1), France(29), Germany(30), India(8), Indonesia(1), Italy(147), Japan(37), Lithuania(6), Malaysia(5), Mexico(7), Mongolia(1), Mozambique(1), Namibia(9), Netherlands(1), Nigeria(2), Paraguay(1), Poland(9), Portugal(18), Romania(36), Russia(6), SaintKittsandNevis(16), Serbia(6), Slovakia(36), SouthAfrica(11), SouthKorea(101), Spain(2), Sweden(1), Switzerland(4), Taiwan(28), Thailand(55), USA(579), Ukraine(31), UnitedKingdom(75), VietNam(65) | 1993.824 [95HPD:1985.97–1999.699] | 7.553×10−4 [95HPD:4.267×10−4-1.141×10−3] |
| PCV-2d | 4,303 | 2003–2024 | Argentina(13), Austria(1), Belgium(6), Bhutan(2), Brazil(22), Burkina Faso(1), Cambodia(5), Canada(13), Chile(8), China(2077), Colombia(77), Denmark(16), Dominican Republic(17), Ethiopia(4), France(56), Germany(40), Hungary(6), India(55), Indonesia(1), Italy(238), Japan(91), Malaysia(77), Mexico(58), Mozambique(4), Netherlands(6), Nigeria(25), Poland(17), Portugal(1), Romania(4), Russia(30), Serbia(2), South Africa(3), South Korea(184), Spain(24), Taiwan(241), Tanzania(16), Thailand(137), USA(555), Ukraine(5), United Kingdom(7), Uruguay(5), Vietnam(153) | 1985.702 [95HPD:1966.41–1995.375] | 6.837×10−4 [95HPD:5.009×10-4-8.832×10−4] |
| PCV-2e | 42 | 2006–2022 | China(8), Italy(9), Mexico(1), South Korea(2), Taiwan(1), USA(21) | 1980.609 [95HPD:1958.747–1994.778] | 4.165×10−4 [95HPD:2.325×10−4-7.618×10-4] |
| PCV-2f | 41 | 1999–2018 | China(11), Croatia(2), India(23), Indonesia(4), Ukraine(1) | 1919.636 [95HPD:1799.726–1982.876] | 6.053×10−4 [95HPD:1.920×10−4-1.649×10−3] |
| PCV-2 g | 34 | 1999–2019 | China(4), India(11), Mongolia(1), Romania(10), South Korea(5), Switzerland(1), Ukraine(1), Vietnam(1) | 1971.456 [95HPD:1941.652–1989.989] | 1.530×10−3 [95HPD:8.623×10−4-2.664×10−3] |
| PCV-2 h | 102 | 2004–2021 | China(15), India(7), Indonesia(1), Japan(1), Romania(2), South Korea(1), Thailand(18), Vietnam(57) | 1979.823 [95HPD:1942.078–1997.499] | 6.253×10−4 [95HPD:3.846×10−4-9.463×10−4] |
Summary of sequences included in the study.
Sequence numbers, collection date ranges, countries (with the number of sequences reported for each county in brackets), tMRCA, and evolutionary rates are reported for each genotype.
3.2 Phylodynamic analysis
The tMRCA ranged from the beginning of the XX century to the 90s, depending on the considered genotype (Table 1). Different genotypes showed substantially consistent evolutionary rates, in the order of 10−4–10−3 substitution/site/year. The comparison of tMRCA and evolutionary rate calculated on the Country−year dataset with the Balanced dataset provided concordant results (Figure 1). Only PCV2b showed an apparently higher evolutionary rate and thus a more recent origin with the Balanced dataset, although a certain 95HPD overlap occurred.
Figure 1
The reconstruction of viral population dynamics based on the Country-year dataset estimated the origin of PCV2a around the beginning of the 20th century. The viral population exhibited a gradual increase following the second half of the 20th century, reaching a peak around the year 2000. This was followed by an apparent decline, with subsequent secondary fluctuations occurring approximately in 2010 and 2015, ultimately leading to a relatively stable population until a final decrease (Figure 2). The origin of PCV2b, estimated to have occurred in the 1980s, was associated with a sharper increase in relative genetic diversity, peaking around 2010. Following this peak, there was a trend toward stabilization and a progressive decline, albeit with several fluctuations. Specifically, a temporary decrease after 2005 was followed by a resurgence around 2015, culminating in a final decline and stabilization by the end of the study period (Figure 2). PCV2d, which shares a similar time to the most recent common ancestor (tMRCA) with PCV2b, exhibited a comparable but delayed pattern, with a progressive and slow increase until 2000, after which a sharper increase occurred, peaking around 2015 and stabilizing thereafter. In all instances, the Balanced dataset provided comparable patterns; however, the viral population increases for both PCV2a and PCV2b were estimated to have a delay of approximately 5 years compared to the Country-year dataset. Additionally, the fluctuations in the Balanced dataset were slightly more pronounced and less smoothed than those observed in the Country-year dataset (Figure 2). The so-called minor genotypes displayed a common trend, characterized by an essentially constant population with a tendency toward a slow, consistent increase, particularly during the period from 2000 to 2015. Notably, PCV2g and PCV2h exhibited a decline in recent years, while PCV2e and PCV2f demonstrated a more stable situation.
Figure 2
The reconstruction of lineages over time, despite some differences in the relative proportions across continents, depicted an overall common trend characterized by the progressive geographic expansion of the major genotypes. Initially, following the inferred tMRCA, an exclusive circulation in Asia was inferred. However, this was followed by a gradual expansion and a more balanced global distribution of PCV genotypes, with Europe and North America emerging as the primary locations harboring most lineages after Asia. A similar trend was observed when analyzing the balanced dataset. The most notable difference occurred with PCV2a, where the Country-year dataset suggested a predominantly Asian circulation until the 1980s, whereas the Balanced dataset estimated also the presence of this genotype in North America during the same period. Beyond this point, the results were consistent across datasets, although the African and European lineages, despite present, were less relevant in the balanced dataset. In the reconstruction of the PCV2b and PCV2d genotypes over time, although a similar trend was observed regardless of the dataset used, the Balanced dataset inferred a higher percentage of lineages circulating in Asia, while a higher presence in Europe instead of North America was reported in the Country-year dataset (Figure 3). In addition, the number of estimated African lineages was lower in the Balanced dataset compared to the Country-year.
Figure 3
The evaluation of location-annotated MCC trees revealed the presence of distinct geographical clustering. However, clades from different continents were interspersed throughout the phylogenetic tree, indicating frequent strain exchanges among different regions, as confirmed by BF-supported migration rates, followed by local independent evolution (Supplementary Figures S1, S2). Additionally, single sequences or small clades were observed, suggesting the occurrence of epidemiological dead ends. The mixing of strains from different origins and the detection of minor clades were more commonly observed in the Country-year dataset.
3.3 Selective pressure analysis
The analysis of sites under pervasive diversifying selection detected positions 47, 63, 134, 191, and 206 for PCV2a, 80, 134, and 190 for PCV2b and 134 and 169 for PCV2d. Episodic diversifying selection was reported at positions 47, 59, 63, 130, 134, 137, 169, 190, and 191 for PCV2a, 2, 3, 30, 59, 68, 80, 88, 130, 131, 134, 190, and 228 for PCV2b and 12, 59, 68, 95, 113, 134, 169, and 234 for PCV2d (Figures 4, 5).
Figure 4
Figure 5
The analysis of positions under diversifying selection shared among genotypes highlighted a turnover of the prevalent amino acid among genotypes in specific positions over time, i.e., the increase in the prevalence of one amino acid in one genotype was sometimes mirrored by a decrease in its frequency in at least one of the other groups (Supplementary Figure S3).
Finally, the comparison of selective pressures strength among genotype pairs, estimated through contrast-FEL, identified a different selective pressure between PCV2a and PCV2b at amino acid positions 76, 123, 141, 190, 206, and 210, between PCV2a and PCV2d at positions 58, 63, 76, 123, 131, 134, 169, and 210, and at positions 58, 63, 141, 169, and 190 between PCV2b and PCV2d (Figures 4, 6).
Figure 6
Overall, PCV2a showed a higher variability in amino acid profile and thus diversification tendency in the considered position compared to PCV2b and PCV2d. When PCV2b and PCV2d were compared, a higher variability featured PCV2b with the main exception of position 169, where a progressive replacement of R → G over years featured PCV2d (Supplementary Figure S4).
4 Discussion
Porcine circovirus 2 is often considered a relatively simple virus under many aspects; however, its genetic background and evolutionary trajectories have proven to be complex and continue to challenge our understanding (; ). The theory of genotype shift has been extensively studied and generally confirmed by molecular epidemiology surveys (; ; ). The mechanism underlying genotype replacement has been attributed to the competitive advantage of certain genetic groups or clades, likely due to differences in virulence, tropism, replication rate or cross-protection. The widespread use of PCV2a-based vaccines is frequently cited as a significant factor contributing to the development of differential fitness among genotypes, which has been particularly detrimental to PCV2a (). However, despite almost two decades have passed since the widespread application of commercial vaccines and the occurrence of genotype shifts, both PCV2a and PCV2b continue to be detected, albeit at lower and variable frequencies (Supplementary Figure S5). In this context, the present study not only confirms the ongoing upward trend of PCV2d but also reconstructs the occurrence of secondary waves for these other genotypes, which followed an initial, prominent wave and its subsequent decline.
The first challenge in PCV2 history reconstruction is represented by the difficulties of ensuring a reliable and objective genotype classification, which could affect population parameter estimation. For example, strains of the newly proposed PCV2i genotype () had previously been classified as PCV2a, and thus the previous classification was maintained (). However, since the present study was not aimed at classification definition, and to ensure that mere classification disagreements did not affect the overall picture, the analysis was repeated considering PCV2i as an independent genotype (data not shown). Although minimal variations in tMRCA and population patterns were observed, the overall pattern of PCV2a fluctuations was confirmed, demonstrating the robustness of the analysis. To further strengthen the results’ reliability, only major, robustly identified, clusters were considered, excluding small intermediate clusters, potentially ascribable to epidemiological dead ends.
The increase in sequence data allowed for a more comprehensive exploration of PCV2 genetic variability with enhanced spatial and temporal resolution, which allows circumventing the “artefactual” effect caused by limited numbers of sequences. The present work includes thousands of sequences for each genotype, as opposed to the few tens or hundreds used in earlier studies like . This reflects a more intense diagnostic and sequencing effort, as well as increased representativeness of the available sequences on a global scale.
Although a strong bias toward high-income countries persists, the inclusion of data from regions and countries where pig farming practices are characterized by different, often less advanced management and less effective control measures has expanded the host population considered in this study. These ecological niches may have contributed to the maintenance and expansion of PCV2 clades that exhibited a fitness disadvantage in more industrialized countries and were thus largely overlooked in previous molecular biology studies (; ). This evidence is particularly suggestive considering the hypothesis that certain PCV2 genotypes may have benefitted from the intensification of the pig farming sector and the introduction of PCV2 vaccines, while others were able to persist in more restricted ecological niches. The essentially stable population estimated for minor genotypes, which exhibited a restricted geographical distribution and occasionally circulated within isolated host populations, may support this observation.
However, the availability of sequences alone can hardly account for the complexity of the observed patterns. Epidemiological factors, like viral dispersal and variable population immunity over time and geographical areas, also play a significant role. Evidence supporting this comes from the comparison of results obtained through the analysis of two random datasets generated using alternative approaches. In fact, selecting up to four sequences per year-country pair has been shown to yield consistent results across repeated trials in previous studies. This method is considered effective and epidemiologically sound, especially when the number of available sequences is influenced by biases in strain collection or sequencing activities over time and geographical area, rather than by actual differences in strain or genotype circulation across various countries or time periods. In scenarios where true variability exists, enforcing an equal sample size for each country-year pair could disproportionately highlight countries with lower viral circulation (that could have been considered responsible for the detection of multiple waves). To address this potential issue, a random subset with the same composition as the original one was generated—excluding several of the rare country-year pairs—analyzed using the same methodology, and compared to the original results (; ). Findings were largely consistent, suggesting that the sequencing bias or subsampling strategy had minimal impact. This consistency underscores the approach robustness even in the face of inevitable study limitations, and confirms that the estimated persistence of PCV2a and PCV2b at non-negligible levels reflects actual epidemiological and evolutionary patterns. Accordingly, the reconstruction of lineages over time supports the progressive expansion and more balanced distribution of all major genotypes at the global level, with increasingly comparable frequencies across the studied regions. While Asia, Europe, and North America continue to show the most significant involvement, South America and Africa are also affected, albeit to a lesser extent. Particularly in the case of Africa, the limited availability of samples likely influenced the results. The inclusion of nearly all available African sequences in the Country-year dataset revealed a more substantial involvement of this region than previously recognized. Given the rising importance of Africa in pig production and its growing economic and commercial relations with other regions, especially Asia, there is an urgent need to gain a better understanding of the epidemiological patterns of PCV2 in Africa (; ).
Similarly, the evaluation of migration events through phylogeographic analysis confirms the remarkable global dispersal of PCV2, characterized by multiple introduction events into new areas, followed by local persistence. Given the likely competition among distinct genotypes and clades—driven by limited host availability and differential cross-protection between homologous and heterologous strains—the periodic introduction of new strains, independently evolved in different environments, may have provided a competitive advantage to these newly colonizing strains.
It is important to emphasize that, based on current knowledge, there is no consistent evidence of significant differential clinical cross-protection among genotypes, and most cases of so-called vaccine failure are likely attributable to improper vaccination management (; ; ). However, there is substantial evidence indicating lower neutralization capabilities of heterologous immunity, as well as higher levels of viremia and viral transmission documented both experimentally and epidemiologically (; ; ; ). Therefore, while not clinically significant, even a marginal differential in cross-protection, when acting on large viral populations, could have impacted the epidemiological and evolutionary landscape.
Whereas previous understanding suggested the periodic emergence of entirely new genotypes, the scenario identified here points more toward periodic fluctuations of currently circulating genotypes. This might be the result of an ongoing evolutionary “arms race” involving different PCV2 clades, with the global pig population serving as the battlefield. The heterogeneous and dynamically changing immunity of this population defines the selective pressures, thereby shaping the viral fitness landscape. According to the observed scenario, we speculate that genotypes with greater biological fitness tend to expand and dominate. However, the rise in prevalence of these dominant genotypes generates immunity in the population, which may drive selective pressures leading to the emergence of new genotypes since the differential cross-protection at the epidemiological scale may confer them a fitness advantage. This selective pressure likely contributed to the replacement of PCV2a by PCV2b, and later, of PCV2b by PCV2d. Vaccination efforts may have further accelerated this process, as immunity against PCV2a strains may have been less effective against PCV2d, facilitating its spread. However, the reduced circulation of PCV2a and PCV2b, combined with the emergence of strains featured by an altered amino acid profile, might have decreased the effectiveness of pre-existing immunity, allowing new wave emergence. Geographical variability and the periodic introduction of new strains with different evolutionary histories may contribute to local differences in genotype fitness. This evolutionary process may represent an example of balancing selection, specifically negative frequency-dependent selection, where a genotype’s fitness diminishes as it becomes more common, and vice versa. While experimental approaches could be considered to test these hypotheses, replicating the complex epidemiological dynamics in a controlled setting presents significant challenges.
The role of environmental conditions and contingencies in affecting PCV2 genotypes’ success, emerges also by the tMRCA estimation of PCV2b and PCV2d. While PCV2d was initially considered a PCV2b-mutant () the divergence between these two genotypes is likely more ancient than previously thought and co-circulated for several years or decades before emerging as major genotypes, as revealed by present and previous phylodynamic and molecular epidemiology studies ().
The pivotal role of host differential immunity was consistently confirmed by all methods used to investigate the characteristics of selective pressures. Most of the detected sites were subjected to episodic rather than diversifying selective pressures, indicating that selection occurs through selective bursts. This scenario aligns well with the hypothesis of the periodic emergence of new genotypic and phenotypic groups that adapt to a changing immune environment, followed by stabilization once a higher fitness phenotype is achieved.
The stronger diversifying selection and most sites under statistically significant positive selection were predominantly located in solvent-accessible regions or on the surface of the capsid protein. Notably, many of these sites correspond to capsid positions previously identified as linear or conformational epitopes in experimental studies, including some recognized as affecting genotype-specific recognition by monoclonal antibodies (; ; ; ; ; ). This result suggests that the evolutionary pressure exerted by host immunity is particularly focused on these exposed regions, driving the adaptation and evolution of the virus in response to immune challenges.
The detection of different sites under significantly different selective pressures among genotypes confirms that PCV2 cannot be considered a uniform entity from an immunological perspective. Distinct selective forces, varying in both location and intensity, act on different genotypes. While it is challenging to determine whether these differences are attributable to structural variations in the capsid or to peculiarities in local host population immunity, the multifactorial nature of PCVDs and its deep interaction with the host suggests that a combination of viral and host factors, but also environmental ones (co-infections, nutrition, management, animal movements, biosecurity, control strategies, and others), are likely to be involved.
Notably, the analysis of amino acid frequency in submitted sequences over time revealed a tendency for different genotypes not to display the same predominant amino acid in epitopic sites. For instance, an increase in the frequency of a particular amino acid or the emergence of a new genotype characterized by a specific amino acid at a given capsid position is sometimes followed by a parallel substitution or decrease in the frequency of that same amino acid in other genotypes. This pattern may be explained by the rise of epitope-specific immunity, which could temporarily decrease the prevalence of a genotype, followed by a resurgence when a new partially immune-escaping profile emerges. This dynamic interplay between viral evolution and host immune pressure underscores the complexity of PCV2 adaptation and persistence within different host populations.
While a direct comparison of the amino acid positions identified in this study with those determined experimentally might be of limited utility—due to the significant differences in the binding of monoclonal antibodies to specific strains in vitro compared to the effects of polyclonal sera acting on a wide array of antigens in a broad population at the epidemiological level—some important considerations can still be made. First, more pronounced fluctuations in the amino acid profiles were observed in PCV2a, particularly from 2005 onwards, which might be linked to the introduction of vaccines. However, similar fluctuations continued to occur thereafter, suggesting the influence of immunity induced by other genotypes as well. Selective pressure analysis and visual inspection of amino acid patterns over time identified a tendency to replace amino acids characteristic of other genotypes. This was notably observed at positions 63, 76, 126, 131, 134, and 190. Similar phenomena, albeit to a lesser extent, were also observed in PCV2b and PCV2d, mainly after 2010. Position 59 is particularly noteworthy, as a decrease in the presence of arginine (R) was observed in PCV2a Cap protein following the emergence of PCV2b, which Cap protein is characterized by this amino acid. Concurrently, PCV2d experienced a decrease in the occurrence of alanine (A), which was the dominant amino acid in PCV2a Cap protein. Both PCV2b and PCV2d showed an increase in the frequency of lysine (K) at position 59 after 2010. While this convergence might seem counterintuitive, lower protection conferred by the R59K mutation has been reported in mutagenesis studies and previously suggested in molecular epidemiology studies as a PCV2a vaccine escaping mechanism (; ). An evolutionary advantage might, therefore, explain the convergence toward specific amino acids in certain positions. A comparable pattern was observed at position 190 T.
5 Conclusion
The results of the present study confirm previous evidence of the alternation of major genotypes on the epidemiological stage and highlight the role of inter-genotype competition and host immunity—including vaccine-induced immunity—in shaping the evolutionary success of specific strains and genotypes. However, the updated and more geographically and temporally representative sequence dataset suggests a negative frequency-dependent selection, allowing the continuous circulation of major genotypes at varying levels over time, rather than the complete genotype replacement initially hypothesized (the so-called “genotype shifts”). This is evidenced by the persistent detection of PCV2a and PCV2b, as well as the less frequently found genotypes, at the time PCV2d is the dominating genotype over the world.
While the determinants of this scenario are challenging to fully elucidate, the present analysis indicates that variations in genotype- or clade-specific immunity—affected by the local prevalence of viral groups—combined with the periodic introduction of strains that have independently evolved in different environments, may have led to periodic fluctuations in the population dynamics of major genotypes over time. These fluctuations are associated with ongoing evolution and variation in the capsid amino acid profile.
This evidence has profound implications for future control strategies. While PCV2d remains the most prevalent and widespread genotype, other genotypes should not be neglected. Efforts should likely focus on fostering broader and more cross-protective immunity rather than targeting a specific genotype. Such an approach would aim not only to prevent clinical outbreaks but also to constrain the evolutionary potential of PCV2.
Statements
Data availability statement
The original contributions presented in the study are included in the article/Supplementary material, further inquiries can be directed to the corresponding author.
Author contributions
GF: Conceptualization, Data curation, Formal analysis, Funding acquisition, Project administration, Writing – original draft, Writing – review & editing. CT: Data curation, Writing – review & editing. ML: Data curation, Writing – review & editing. MD: Writing – review & editing. JS: Conceptualization, Project administration, Writing – original draft, Writing – review & editing.
Funding
The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work was supported by the Department of Animal Medicine, Production and Health, University of Padua (grant number BIRD225455/22) and Open Access funding provided by Università degli Studi di Padova, University of Padua, Open Science Committee.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmicb.2024.1500498/full#supplementary-material
References
1
AbascalF.ZardoyaR.TelfordM. J. (2010). TranslatorX: multiple alignment of nucleotide sequences guided by amino acid translations. Nucleic Acids Res.38, W7–W13. doi: 10.1093/nar/gkq291
2
BaeleG.LiW. L. S.DrummondA. J.SuchardM. A.LemeyP. (2013). Accurate model selection of relaxed molecular clocks in Bayesian phylogenetics. Mol. Biol. Evol.30, 239–243. doi: 10.1093/molbev/mss243
3
BandrickM.BalaschM.HeinzA.TaylorL.KingV.ToepferJ.et al. (2022). A bivalent porcine circovirus type 2 (PCV2), PCV2a-PCV2b, vaccine offers biologically superior protection compared to monovalent PCV2 vaccines. Vet. Res.53:12. doi: 10.1186/s13567-022-01029-w
4
BielejecF.BaeleG.VranckenB.SuchardM. A.RambautA.LemeyP. (2016). SpreaD3: interactive visualization of spatiotemporal history and trait evolutionary processes. Mol. Biol. Evol.33, 2167–2169. doi: 10.1093/molbev/msw082
5
ChoiC.-Y.ChoiY.-C.ParkI.-B.LeeC.-H.KangS.-J.ChunT. (2018). The ORF5 protein of porcine circovirus type 2 enhances viral replication by dampening type I interferon expression in porcine epithelial cells. Vet. Microbiol.226, 50–58. doi: 10.1016/J.VETMIC.2018.10.005
6
CorteyM.PileriE.SibilaM.PujolsJ.BalaschM.PlanaJ.et al. (2011). Genotypic shift of porcine circovirus type 2 from PCV-2a to PCV-2b in Spain from 1985 to 2008. Vet. J.187, 363–368. doi: 10.1016/j.tvjl.2009.12.023
7
DarribaD.TaboadaG. L.DoalloR.PosadaD. (2012). JModelTest 2: more models, new heuristics and parallel computing. Nat. Methods9:772. doi: 10.1038/nmeth.2109
8
DrummondA. J.HoS. Y. W.PhillipsM. J.RambautA. (2006). Relaxed phylogenetics and dating with confidence. PLoS Biol.4, e88–e710. doi: 10.1371/journal.pbio.0040088
9
DundonW. G.MoliniU.FranzoG. (2024). Six underreported viral diseases of domesticated and wild swine in Africa: implications and perspectives. Vet. Microbiol.294:110120. doi: 10.1016/j.vetmic.2024.110120
10
DupontK.NielsenE. O.BækboP.LarsenL. E. (2008). Genomic analysis of PCV2 isolates from Danish archives and a current PMWS case-control study supports a shift in genotypes with time. Vet. Microbiol.128, 56–64. doi: 10.1016/j.vetmic.2007.09.016
11
DvorakC. M. T.YangY.HaleyC.SharmaN.MurtaughM. P. (2016). National reduction in porcine circovirus type 2 prevalence following introduction of vaccination. Vet. Microbiol.189, 86–90. doi: 10.1016/j.vetmic.2016.05.002
12
FaustiniG.TucciaroneC. M.LegnardiM.GrassiL.BertoG.DrigoM.et al. (2023). Into the backyard: multiple detections of PCV-2e in rural pig farms of northern Italy. An unexpected ecological niche?Prev. Vet. Med.216:105943. doi: 10.1016/j.prevetmed.2023.105943
13
FinsterbuschT.MankertzA. (2009). Porcine circoviruses-small but powerful. Virus Res.143, 177–183. doi: 10.1016/j.virusres.2009.02.009
14
FranzoG.CorteyM.SegalésJ.HughesJ.DrigoM. (2016a). Phylodynamic analysis of porcine circovirus type 2 reveals global waves of emerging genotypes and the circulation of recombinant forms. Mol. Phylogenet. Evol.100, 269–280. doi: 10.1016/j.ympev.2016.04.028
15
FranzoG.SegalésJ. (2018). Porcine circovirus 2 (PCV-2) genotype update and proposal of a new genotyping methodology. PLoS One13:e0208585. doi: 10.1371/journal.pone.0208585
16
FranzoG.SegalésJ. (2020). Porcine circovirus 2 genotypes, immunity and vaccines: multiple genotypes but one single serotype. Pathogens9, 1–12. doi: 10.3390/pathogens9121049
17
FranzoG.TucciaroneC. M.CecchinatoM.DrigoM. (2016b). Porcine circovirus type 2 (PCV2) evolution before and after the vaccination introduction: a large scale epidemiological study. Sci. Rep.6:39458. doi: 10.1038/srep39458
18
FranzoG.ZerboH. L.OuobaB. L.Dji-TomboA. D.KindoM. G.SawadogoR.et al. (2023). A Phylogeographic analysis of porcine parvovirus 1 in Africa. Viruses15:207. doi: 10.3390/v15010207
19
GaoZ.DongQ.JiangY.OpriessnigT.WangJ.QuanY.et al. (2014). ORF4-protein deficient PCV2 mutants enhance virus-induced apoptosis and show differential expression of mRNAs in vitro. Virus Res.183, 56–62. doi: 10.1016/j.virusres.2014.01.024
20
HallM. D.WoolhouseM. E. J.RambautA. (2016). The effects of sampling strategy on the quality of reconstruction of viral population dynamics using Bayesian skyline family coalescent methods: a simulation study. Virus Evol2:vew003. doi: 10.1093/ve/vew003
21
HillV.BaeleG. (2019). Bayesian estimation of past population dynamics in BEAST 1.10 using the Skygrid coalescent model. Mol. Biol. Evol.36, 2620–2628. doi: 10.1093/molbev/msz172
22
HuangL. P.LuY. H.WeiY. W.GuoL. J.LiuC. M. (2011). Identification of one critical amino acid that determines a conformational neutralizing epitope in the capsid protein of porcine circovirus type 2. BMC Microbiol.11:188. doi: 10.1186/1471-2180-11-188
23
HuangL.SunZ.XiaD.WeiY.SunE.LiuC.et al. (2020). Neutralization mechanism of a monoclonal antibody targeting a porcine circovirus type 2 cap protein conformational epitope. J. Virol.94:e01836-19. doi: 10.1128/jvi.01836-19
24
KangS.-J.KangH.YuS.-H.LeeH. J.LeeN.HyunB.-H.et al. (2019). Genetic diversity and different cross-neutralization capability of porcine circovirus type 2 isolates recently circulating in South Korea. BMC Vet. Res.16:334. doi: 10.1186/s12917-020-02549-3
25
KaruppannanA. K.KwangJ. (2011). ORF3 of porcine circovirus 2 enhances the in vitro and in vivo spread of the of the virus. Virology410, 248–256. doi: 10.1016/j.virol.2010.11.009
26
KaruppannanA. K.OpriessnigT. (2017). Porcine circovirus type 2 (PCV2) vaccines in the context of current molecular epidemiology. Viruses9:99. doi: 10.3390/v9050099
27
Kosakovsky PondS. L.FrostS. D. W.MuseS. V. (2005). HyPhy: hypothesis testing using phylogenies. Bioinformatics21, 676–679. doi: 10.1093/bioinformatics/bti079
28
Kosakovsky PondS. L.PosadaD.GravenorM. B.WoelkC. H.FrostS. D. W. (2006). GARD: a genetic algorithm for recombination detection. Bioinformatics22, 3096–3098. doi: 10.1093/bioinformatics/btl474
29
Kosakovsky PondS. L.WisotskyS. R.EscalanteA.MagalisB. R.WeaverS. (2021). Contrast-FEL - a test for differences in selective pressures at individual sites among clades and sets of branches. Mol. Biol. Evol.38, 1184–1198. doi: 10.1093/molbev/msaa263
30
LayanM.MüllerN. F.DellicourS.De MaioN.BourhyH.CauchemezS.et al. (2023). Impact and mitigation of sampling bias to determine viral spread: evaluating discrete phylogeography through CTMC modeling and structured coalescent model approximations. Virus Evol.9:vead010. doi: 10.1093/VE/VEAD010
31
LekcharoensukP.MorozovI.PaulP. S.ThangthumniyomN.WajjawalkuW.MengX. J. (2004). Epitope mapping of the major capsid protein of type 2 porcine circovirus (PCV2) by using chimeric PCV1 and PCV2. J. Virol.78, 8135–8145. doi: 10.1128/JVI.78.15.8135-8145.2004
32
LemeyP.RambautA.DrummondA. J.SuchardM. A. (2009). Bayesian phylogeography finds its roots. PLoS Comput. Biol.5:e1000520. doi: 10.1371/journal.pcbi.1000520
33
LiD.WangJ.XuS.CaiS.AoC.FangL.et al. (2018). Identification and functional analysis of the novel ORF6 protein of porcine circovirus type 2 in vitro. Vet. Res. Commun.42, 1–10. doi: 10.1007/s11259-017-9702-0
34
LiuJ.HuangL.WeiY.TangQ.LiuD.WangY.et al. (2013). Amino acid mutations in the capsid protein produce novel porcine circovirus type 2 neutralizing epitopes. Vet. Microbiol.165, 260–267. doi: 10.1016/j.vetmic.2013.03.013
35
LvQ.GuoK.ZhangY. (2014). Current understanding of genomic DNA of porcine circovirus type 2. Virus Genes49, 1–10. doi: 10.1007/s11262-014-1099-z
36
MahéD.BlanchardP.TruongC.ArnauldC.Le CannP.CarioletR.et al. (2000). Differential recognition of ORF2 protein from type 1 and type 2 porcine circoviruses and identification of immunorelevant epitopes. J. Gen. Virol.81, 1815–1824. doi: 10.1099/0022-1317-81-7-1815
37
MoliniU.FranzoG.GousL.MollerS.HembergerY. M.ChiwomeB.et al. (2021). Three different genotypes of porcine circovirus 2 (PCV-2) identified in pigs and warthogs in Namibia. Arch. Virol.166, 1723–1728. doi: 10.1007/s00705-021-05035-9
38
MurrellB.MoolaS.MabonaA.WeighillT.ShewardD.Kosakovsky PondS. L.et al. (2013). FUBAR: a fast, unconstrained bayesian AppRoximation for inferring selection. Mol. Biol. Evol.30, 1196–1205. doi: 10.1093/molbev/mst030
39
MurrellB.WertheimJ. O.MoolaS.WeighillT.SchefflerK.Kosakovsky PondS. L. (2012). Detecting individual sites subject to episodic diversifying selection. PLoS Genet.8:e1002764. doi: 10.1371/journal.pgen.1002764
40
NguyenL. T.SchmidtH. A.Von HaeselerA.MinhB. Q. (2015). IQ-TREE: a fast and effective stochastic algorithm for estimating maximum-likelihood phylogenies. Mol. Biol. Evol.32, 268–274. doi: 10.1093/molbev/msu300
41
OpriessnigT.KaruppannanA. K.CastroA. M. M. G.XiaoC. T. (2020a). Porcine circoviruses: current status, knowledge gaps and challenges. Virus Res.286:198044. doi: 10.1016/j.virusres.2020.198044
42
OpriessnigT.KaruppannanA. K.HalburP. G.CalvertJ. G.NitzelG. P.MatzingerS. R.et al. (2020b). Porcine circovirus type 2a or 2b based experimental vaccines provide protection against PCV2d/porcine parvovirus 2 co-challenge. Vaccine38, 1975–1981. doi: 10.1016/j.vaccine.2020.01.013
43
OpriessnigT.O’NeillK.GerberP. F.de CastroA. M. M. G.Gimenéz-LirolaL. G.BeachN. M.et al. (2013a). A PCV2 vaccine based on genotype 2b is more effective than a 2a-based vaccine to protect against PCV2b or combined PCV2a/2b viremia in pigs with concurrent PCV2, PRRSV and PPV infection. Vaccine31, 487–494. doi: 10.1016/j.vaccine.2012.11.030
44
OpriessnigT.XiaoC. T.HalburP. G.GerberP. F.MatzingerS. R.MengX. J. (2017). A commercial porcine circovirus (PCV) type 2a-based vaccine reduces PCV2d viremia and shedding and prevents PCV2d transmission to naïve pigs under experimental conditions. Vaccine35, 248–254. doi: 10.1016/j.vaccine.2016.11.085
45
OpriessnigT.XiaoC.-T.GerberP. F.HalburP. G. (2013b). Emergence of a novel mutant PCV2b variant associated with clinical PCVAD in two vaccinated pig farms in the U.S. concurrently infected with PPV2. Vet. Microbiol.163, 177–183. doi: 10.1016/j.vetmic.2012.12.019
46
PettersenE. F.GoddardT. D.HuangC. C.CouchG. S.GreenblattD. M.MengE. C.et al. (2004). UCSF chimera - a visualization system for exploratory research and analysis. J. Comput. Chem.25, 1605–1612. doi: 10.1002/jcc.20084
47
ReinerG.HofmeisterR.WillemsH. (2015). Genetic variability of porcine circovirus 2 (PCV2) field isolates from vaccinated and non-vaccinated pig herds in Germany. Vet. Microbiol.180, 41–48. doi: 10.1016/j.vetmic.2015.07.026
48
SahaD.HuangL.BussalleuE.LefebvreD. J.FortM.Van DoorsselaereJ.et al. (2012a). Antigenic subtyping and epitopes’ competition analysis of porcine circovirus type 2 using monoclonal antibodies. Vet. Microbiol.157, 13–22. doi: 10.1016/j.vetmic.2011.11.030
49
SahaD.LefebvreD. J.OomsK.HuangL.DelputteP. L.van DoorsselaereJ.et al. (2012b). Single amino acid mutations in the capsid switch the neutralization phenotype of porcine circovirus 2. J. Gen. Virol.93, 1548–1555. doi: 10.1099/vir.0.042085-0
50
SegalésJ.SibilaM. (2022). Revisiting porcine circovirus disease diagnostic criteria in the current porcine circovirus 2 epidemiological context. Vet Sci9:110. doi: 10.3390/vetsci9030110
51
SeoH. W.ParkC.KangI.ChoiK.JeongJ.ParkS. J.et al. (2014). Genetic and antigenic characterization of a newly emerging porcine circovirus type 2b mutant first isolated in cases of vaccine failure in Korea. Arch. Virol.159, 3107–3111. doi: 10.1007/s00705-014-2164-6
52
ShangS. B.JinY. L.JiangX.ZhouJ. Y.ZhangX.XingG.et al. (2009). Fine mapping of antigenic epitopes on capsid proteins of porcine circovirus, and antigenic phenotype of porcine circovirus type 2. Mol. Immunol.46, 327–334. doi: 10.1016/j.molimm.2008.10.028
53
ShenH. G.HalburP. G.OpriessnigT. (2012). Prevalence and phylogenetic analysis of the current porcine circovirus 2 genotypes after implementation of widespread vaccination programmes in the USA. J. Gen. Virol.93, 1345–1355. doi: 10.1099/vir.0.039552-0
54
SibilaM.RoccoC.FranzoG.HuertaE.DomingoM.NúñezJ. I.et al. (2021). Genotyping of porcine circovirus 2 (Pcv-2) in vaccinated pigs suffering from pcv-2-systemic disease between 2009 and 2020 in Spain. Pathogens10:1016. doi: 10.3390/pathogens10081016
55
StandleyK. (2013). MAFFT multiple sequence alignment software version 7: improvements in performance and usability (outlines version 7). Mol. Biol. Evol.30, 772–780. doi: 10.1093/molbev/mst010
56
SuchardM. A.LemeyP.BaeleG.AyresD. L.DrummondA. J.RambautA. (2018). Bayesian phylogenetic and phylodynamic data integration using BEAST 1.10. Virus Evol.4:vey016. doi: 10.1093/ve/vey016
57
TribleB. R.KerriganM.CrosslandN.PotterM.FaabergK.HesseR.et al. (2011). Antibody recognition of porcine circovirus type 2 capsid protein epitopes after vaccination, infection, and disease. Clin. Vaccine Immunol.18, 749–757. doi: 10.1128/CVI.00418-10
58
VarsaniA.HarrachB.RoumagnacP.BenkőM.BreitbartM.DelwartE.et al. (2024). 2024 taxonomy update for the family Circoviridae. Arch. Virol.169:176. doi: 10.1007/s00705-024-06107-2
59
WangY.NollL.LuN.PorterE.StoyC.ZhengW.et al. (2020). Genetic diversity and prevalence of porcine circovirus type 3 (PCV3) and type 2 (PCV2) in the Midwest of the USA during 2016–2018. Transbound. Emerg. Dis.67, 1284–1294. doi: 10.1111/TBED.13467
60
WeaverS.ShankS. D.SpielmanS. J.LiM.MuseS. V.Kosakovsky PondS. L. (2018). Datamonkey 2.0: a modern web application for characterizing selective and other evolutionary processes. Mol. Biol. Evol.35, 773–777. doi: 10.1093/MOLBEV/MSX335
61
XiaoC.-T.HalburP. G.OpriessnigT. (2012). Complete genome sequence of a novel porcine circovirus type 2b variant present in cases of vaccine failures in the United States. J. Virol.86, –12469. doi: 10.1128/JVI.02345-12
Summary
Keywords
porcine circovirus 2 (PCV2), genotypes, evolution, phylodynamic, phylogeography, selection
Citation
Franzo G, Tucciarone CM, Legnardi M, Drigo M and Segalés J (2024) An updated phylogeography and population dynamics of porcine circovirus 2 genotypes: are they reaching an equilibrium?. Front. Microbiol. 15:1500498. doi: 10.3389/fmicb.2024.1500498
Received
23 September 2024
Accepted
18 October 2024
Published
29 October 2024
Volume
15 - 2024
Edited by
Anna Luganini, University of Turin, Italy
Reviewed by
Guido Alberto König, Instituto Nacional de Tecnología Agropecuaria, Argentina
Babatunde Olanrewaju Motayo, Federal Medical Centre, Abeokuta, Nigeria
Updates
Copyright
© 2024 Franzo, Tucciarone, Legnardi, Drigo and Segalés.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Giovanni Franzo, giovanni.franzo@unipd.it
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.